You are here: Industry Insights > VELSIPITY

News List

Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area PharmaSources
December 24, 2024
Everest Medicines announced that the first prescription for VELSIPITY(R) has been written at Foshan Fosun Chancheng Hospital in Guangdong.
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY Everest Medicines Limited
December 20, 2024
Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients PharmaSources
December 12, 2024
Everest Medicines today announced that the first prescription of VELSIPITY® (etrasimod) has been issued on December 11th at Kiang Wu Hospital in Macau.
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong PharmaSources
December 03, 2024
Everest Medicines today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everest’s New Drug Application (NDA).